Business context and reporting period
This is Atlas Holdings, Inc.’s 2017 Form 10-K, covering its formation on October 4, 2017 through December 31, 2017—not an operating-company report for Amneal Pharmaceuticals, Inc. Atlas was a shell formed to facilitate the proposed combination of Impax Laboratories and Amneal Pharmaceuticals LLC. At year-end, Impax owned all 1,000 Atlas shares; Atlas reported no operating activities. The filing’s financial statements were audited by KPMG, which gave an unqualified opinion.
Financial results and position
- Revenue, expenses and earnings: The statements show dashes for net revenue, operating expenses, income taxes and net loss; no operating results were reported.
- Cash flow and liquidity: Cash-flow statement line items and ending cash are shown as dashes. Total current assets and total assets were reported as zero.
- Debt and liabilities: Total current liabilities and total liabilities were reported as zero. Atlas reported no material assets or liabilities at December 31, 2017.
- Equity: Common stock was $10, offset by a $10 stockholder receivable due from Impax; total stockholders’ equity was zero.
- Margins and comparable-period change: Not meaningful for this shell entity. No prior comparable operating period is presented.
Material changes, outlook and risks
The principal development was the pending combination of Impax and Amneal under Atlas, which was expected to close in the first half of 2018, subject to shareholder, antitrust and NYSE listing conditions. Following closing, Atlas was expected to be renamed Amneal Pharmaceuticals, Inc.; Impax shareholders were expected to receive about 25% and existing Amneal members about 75% of the combined company’s voting and economic interests before the described PIPE investment. After the PIPE investment, existing Amneal members were expected to hold about 60% of voting power and institutional investors about 15%.
- The filing warns that regulatory review, shareholder approval, litigation or other closing conditions could delay or prevent the combination. Two securities class actions alleged disclosure deficiencies in the transaction registration statement and sought, among other relief, to enjoin the deal.
- Integration costs and execution challenges, customer or supplier disruption, employee losses, and failure to realize anticipated synergies could impair the combined business. The filing says integration costs were not yet estimable.
- The combined company was expected to have substantial indebtedness, but this Atlas filing provides no clear amount. Risks described include debt-service demands, variable interest rates, restrictive covenants, refinancing and liquidity constraints.
- Existing Amneal members were expected to retain control, with board designation and consent rights; the combined company was expected to be a controlled company and not pay cash dividends in the foreseeable future.
- A subsequent event disclosed board approval of a proposed 2018 incentive plan with 23 million Class A shares initially available, subject to shareholder approval and completion of the combination.
Investor facts to verify
- Whether the combination closed, on what terms, and whether required regulatory and shareholder approvals were obtained.
- The combined company’s actual debt, financing terms, liquidity and post-closing cash flows; the 2017 Atlas shell statements do not provide these operating-company figures.
- The resolution and financial impact, if any, of the securities litigation and other transaction contingencies.
- Whether projected ownership, PIPE investment, integration plans and anticipated synergies were realized.
- Whether the 2018 incentive plan was approved and how share issuance affected dilution.